PRESS RELEASE published on 02/17/2024 at 01:50, 2 years 4 months ago BioNxt Solutions Finalizes Agreement BioNxt Solutions Inc. finalizes Settlement Agreement with a creditor to settle $282,415 debt through issuance of common shares and a cash payment. Debt to be settled in three instalments of shares based on market price Common Shares Debt Settlement BioNxt Solutions Inc. Settlement Agreement Creditor
PRESS RELEASE published on 01/30/2024 at 05:48, 2 years 5 months ago BIONXT SOLUTIONS ANNOUNCES CLOSING OF FINAL TRANCHE OF NON-BROKERED PRIVATE PLACEMENT BioNxt Solutions Inc. closes final tranche of non-brokered private placement, raising gross proceeds of $288,000 to fund drug development and working capital purposes Private Placement Working Capital Investment Drug Development BioNxt Solutions Inc.
PRESS RELEASE published on 12/22/2023 at 09:05, 2 years 6 months ago BioNxt Solutions Announces Completion of Cladribine ODF Toxicity Study and Financing
PRESS RELEASE published on 12/22/2023 at 01:50, 2 years 6 months ago BioNxt Solutions Announces Completion of Cladribine ODF Toxicity Study and Financing
PRESS RELEASE published on 12/12/2023 at 09:05, 2 years 6 months ago BioNxt Receives Delivery of Premium Commercial Coating and Cutting Equipment for Commercial Manufacturing of Drug Delivery Products
PRESS RELEASE published on 12/09/2023 at 04:30, 2 years 7 months ago BioNxt Solutions Announces Completion of Debenture and Interest Settlement and Issuance of Finder’s Warrants
PRESS RELEASE published on 11/25/2023 at 01:44, 2 years 7 months ago Bionxt Solutions Announces Convertible Debenture and Interest Settlement
PRESS RELEASE published on 11/20/2023 at 09:05, 2 years 7 months ago BioNxt Accelerates Cladribine ODF Clinical and Commercialization Strategy for Multiple Sclerosis Treament
PRESS RELEASE published on 11/15/2023 at 09:05, 2 years 7 months ago BioNxt Reports on New Cladrabine ODF Product Development and Commercialization Program
PRESS RELEASE published on 11/13/2023 at 09:05, 2 years 7 months ago BioNxt Signs Definitive Agreement For 100% Acquisition of IP And Co-Development of Cladribine ODF Drug Reformulation for The Treatment of Multiple Sclerosis
Published on 07/10/2026 at 08:00, 25 minutes ago Caledonia Mining Corporation Plc: Notification of Relevant Change to Significant Shareholder
Published on 07/10/2026 at 00:10, 8 hours 15 minutes ago Core Silver and Arcus Enter Into Definitive Arrangement Agreement for Business Combination
Published on 07/10/2026 at 00:10, 8 hours 15 minutes ago Core Silver and Arcus Enter Into Definitive Arrangement Agreement for Business Combination
Published on 07/09/2026 at 23:05, 9 hours 20 minutes ago Caldwell Reports Third Quarter Results and Announces Increase of Quarterly Dividend
Published on 07/09/2026 at 22:30, 9 hours 55 minutes ago Rio Grande Resources Announces Equity Grants
Published on 07/10/2026 at 07:59, 25 minutes ago Turkiye Garanti Bankasi A.S.: CMB Approval for Bond Issuance to Foreign Markets
Published on 07/10/2026 at 07:54, 30 minutes ago EQS-Adhoc: Bayer Aktiengesellschaft: Bayer secures 3.0 billion euros to improve capital structure
Published on 07/10/2026 at 07:22, 1 hour 2 minutes ago Correction of a release from 09.07.2026 08:00 GMT/BST - Official List Notice
Published on 07/10/2026 at 07:05, 1 hour 19 minutes ago The 26th CIFIT Promotes September Fair Through Hong Kong and Macao Roadshows
Published on 07/10/2026 at 07:00, 1 hour 25 minutes ago DKSH Performance Materials Scales its Personal Care Business by Acquiring Gale & Cosm in Italy
Published on 07/09/2026 at 18:00, 14 hours 25 minutes ago Second-quarter 2026 activity: +7% (vs. Q2 2025)
Published on 07/09/2026 at 18:00, 14 hours 25 minutes ago Half-year report on Deezer’s liquidity contract with BNP Paribas
Published on 07/09/2026 at 17:45, 14 hours 40 minutes ago Air Liquide to invest over 200M USD to support chemical manufacturing expansion in Texas
Published on 07/09/2026 at 15:50, 16 hours 34 minutes ago Statement about the number of shares composing the share capital and the number of voting rights as of June 30, 2026
